Samsung Bioepis starts to develop new drug for acute pancreatitis

Published: 2018-08-14 22:40:00
Updated: 2018-08-14 22:54:21

Samsung Bioepis(CEO/President Han-Seung Ko) will start to develop new drugs for acute pancreatitis.

Samsung Bioepis said they would conduct a Phase I clinical trial for an acute pancreatitis therapy candidate(project name: SB26, TAK-671) being developed jointly with Japanese Takeda Pharmaceutica...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.